Skip to main content

Animations

Illustrated close up of DNA.

Research Tools Catalog

To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.

Helpful Resources

  • Illustrated adjacent hexagons.

    Sponsored Tools Program

    Learn more about how MJFF can help share your tools.

  • Illustrated Parkinson's Disease Research Tools Consortium logo.

    Tools Consortium

    MJFF is working with industry to develop priority tools.

  • Illustrated brain on a presentation display.

    Preclinical Models

    Learn more about the various in vivo models used in Parkinson's disease research.

Find a Research Tool

Filter by Tool Type or Gene/Protein Type to Organize Results

* = MJFF does not control pricing or terms of availability for this tool. 

Filters
Sort options
Sort by
Order
Filters
Sort options
Sort by
Order
Sort options
Sort by
Order
Results (277)
Sort by:
AAV2/5 CBh WT Alpha-Synuclein Plasmid
DNA Plasmids
Viral transgene plasmid used in the AAV2/5 WT alpha-synuclein viral vector available through Charles River Labs (see viral vector section). This plasmid is available to non-profit and for-profit groups. RRID:Addgene_194244
  • Alpha-Synuclein
ATP13A2 Antibody
Antibody
Rabbit monoclonal antibody directed against mouse ATP13A2 for immunoblotting, immunostaining, and immunoprecipitation applications.  Estimated Availability: Early 2026
  • ATP13A2
Floxed S69R Rab32 Mouse
Mouse Model
Mouse expressing the S69R point mutation in the mouse Rab32 gene (corresponds to the S71R mutation in human Rab32). LoxP sites flank the Rab32 gene to enable conditional Cre-mediated knockout.  Estimated Availability: Early 2026
  • Rab
iMCI-PARK Mouse*
Mouse Model
Inducible MCI-PARK (iMCI-PARK) mice, based on the ESR-NDUFS2 strain described by Fernández-Agüera, 2015, were generated by crossing mice carrying a floxed allele of mouse Ndufs2 with mice that broadly express tamoxifen-inducible cre recombinase (Tg(CAG-cre/Esr1*)5Amc that result in a conditional, body-wide knock-out of Ndufs2 following tamoxifen induction. Model was originally designed by deleting Ndufs2 only from dopaminergic neurons by D. James Surmeier at Northwestern University and made available through the MJFF Sponsored Tools Program. RRID:IMSR_JAX:038571
  • Ndufs2
LRRK2 KO Rat
Rat Model
CRISPR/Cas9 genome targeting strategy to knockout LRRK2 on a Sprague Dawley rat background. Estimated Availability: Early 2026
  • LRRK2
Parkin KO x Polg Mutator Mouse*
Mouse Model
Parkin KO x Polg Mutator mice were generated by crossing PolgAD257A mutant mice, lacking mitochondria polymerase proofreading function, with Parkin KO mice. Model was designed by Kelly Stauch and Howard Fox at University of Nebraska Medical Center and made available through the MJFF Sponsored Tools Program. RRID:IMSR_JAX:036670
  • Parkin
  • PolG
Parkin KO Rat
Rat Model
CRISPR/Cas9 genome targeting strategy to knockout Parkin on a Sprague Dawley rat background. Estimated Availability: Late 2025
  • Parkin
PINK1 KO Rat
Rat Model
CRISPR/Cas9 genome targeting strategy to knockout PINK1 on a Sprague Dawley rat background. Estimated Availability: Late 2025
  • PINK1
SNCA Triplication iPSC line set*
Human iPS Cell
iPSC line derived from a patient with the SNCA triplication mutation. Corrected lines with normal SNCA expression levels and TdTomato reporter KI versions of the lines will also be available. These lines were generated and kindly deposited by Vik Khurana into the MJFF Sponsored Tools Program.  Expected Availability: Late 2025
  • Alpha-Synuclein
Ubiquitin pS65 Phosphospecific Antibody (WB/ICC/ELISA)
Antibody
Rabbit monoclonal phosphospecific antibody directed against Serine65 of ubiquitin. Suitable for immunoblot, immunocytochemistry, and ELISA applications.   
  • Ubiquitin
Have questions or need additional information?

Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page. 

"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD Mayo Clinic
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.